Ignite Creation Date:
2024-06-16 @ 11:52 AM
Last Modification Date:
2024-10-26 @ 3:32 PM
Study NCT ID:
NCT06457425
Status:
RECRUITING
Last Update Posted:
2024-06-13
First Post:
2024-06-07
Brief Title:
Flunotinib Maleate Phase II Intermediate-High Risk Bone Fiber Clinical Trial
Sponsor:
Chengdu Zenitar Biomedical Technology Co Ltd
Organization:
Chengdu Zenitar Biomedical Technology Co Ltd
Study Overview
Official Title:
An Open Positive Drug-controlled Parallel-group Multicenter Phase II Clinical Trial of the Efficacy Safety and Pharmacokinetics of Flunotinib Maleate Tablets in the Treatment of Patients With Intermediate- and High-risk Myelofibrosis
Status:
RECRUITING
Status Verified Date:
2024-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This trial adopts a multicenter open-label positive drug parallel control clinical trial design planning to enroll approximately 75 MF participants Eligible participants will be stratified and assigned in a 111 ratio to the low-dose fruquintinib maleate tablet group high-dose fruquintinib maleate tablet group or the ruxolitinib tablet group Stratification factors include the Dynamic International Prognostic Scoring System DIPSS risk classification intermediate-2 and high risk
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None